Published in COPD on February 01, 2012
Sinogram Affirmed Iterative Reconstruction (SAFIRE) versus weighted filtered back projection (WFBP) effects on quantitative measure in the COPDGene 2 test object. Med Phys (2014) 0.94
Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med (2014) 0.93
Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 0.87
Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort. BMC Pulm Med (2016) 0.86
Impact of steroid medication before hospital admission on barotrauma in mechanically ventilated patients with acute respiratory distress syndrome in intensive care units. J Anesth (2014) 0.75
ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 31.79
Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med (1999) 29.97
Interpretative strategies for lung function tests. Eur Respir J (2005) 21.50
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med (2004) 18.60
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 10.05
Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax (2002) 8.77
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax (2004) 8.09
Genetic epidemiology of COPD (COPDGene) study design. COPD (2010) 7.67
Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J (1995) 7.03
Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) Am J Respir Crit Care Med (1996) 5.82
Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 5.49
Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest (2002) 3.82
Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med (2006) 3.71
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2000) 3.63
Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis (1986) 3.03
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med (1997) 2.77
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2008) 2.66
The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J (2004) 2.63
Airway and systemic inflammation and decline in lung function in patients with COPD. Chest (2005) 2.59
Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med (1997) 2.45
Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med (2002) 2.41
Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis (1979) 2.06
Impact of COPD exacerbations on patient-centered outcomes. Chest (2007) 1.36
Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J (1994) 1.26
Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2005) 0.98
Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol (2008) 0.91
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Genetic epidemiology of COPD (COPDGene) study design. COPD (2010) 7.67
A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol (2007) 6.33
A randomized study of endobronchial valves for advanced emphysema. N Engl J Med (2010) 6.23
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol (2004) 5.57
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
Genomic screening and replication using the same data set in family-based association testing. Nat Genet (2005) 5.44
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation (2007) 5.05
Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med (2011) 4.75
PBAT: tools for family-based association studies. Am J Hum Genet (2004) 4.68
Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg (2010) 4.59
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
MMP12, lung function, and COPD in high-risk populations. N Engl J Med (2009) 3.96
An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 3.92
A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet (2009) 3.78
Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70
A multivariate family-based association test using generalized estimating equations: FBAT-GEE. Biostatistics (2003) 3.52
Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet (2010) 3.44
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet (2009) 3.41
On the replication of genetic associations: timing can be everything! Am J Hum Genet (2008) 3.32
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol (2010) 3.22
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA (2004) 3.07
The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Fam Pract (2011) 3.06
Mutation of the COG complex subunit gene COG7 causes a lethal congenital disorder. Nat Med (2004) 3.06
The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med (2007) 2.91
Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med (2007) 2.77
Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med (2004) 2.62
Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg (2006) 2.53
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52
The SERPINE2 gene is associated with chronic obstructive pulmonary disease. Am J Hum Genet (2005) 2.46
Lower bronchodilator responsiveness in Puerto Rican than in Mexican subjects with asthma. Am J Respir Crit Care Med (2003) 2.39
Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol (2008) 2.38
The association of a SNP upstream of INSIG2 with body mass index is reproduced in several but not all cohorts. PLoS Genet (2007) 2.35
Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest (2015) 2.32
The clinical features of the overlap between COPD and asthma. Respir Res (2011) 2.29
Association of vitamin D receptor gene polymorphisms with childhood and adult asthma. Am J Respir Crit Care Med (2004) 2.24
Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2008) 2.20
The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet (2004) 2.19
Refractory asthma: importance of bronchoscopy to identify phenotypes and direct therapy. Chest (2011) 2.19
Using the noninformative families in family-based association tests: a powerful new testing strategy. Am J Hum Genet (2003) 2.18
Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. Thorax (2012) 2.15
A family-based association test for repeatedly measured quantitative traits adjusting for unknown environmental and/or polygenic effects. Stat Appl Genet Mol Biol (2004) 2.15
Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med (2014) 2.14
Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet (2004) 2.14
Progression of asthma measured by lung function in the childhood asthma management program. Am J Respir Crit Care Med (2004) 2.12
Assessing the reproducibility of asthma candidate gene associations, using genome-wide data. Am J Respir Crit Care Med (2009) 2.10
Distinct quantitative computed tomography emphysema patterns are associated with physiology and function in smokers. Am J Respir Crit Care Med (2013) 2.09
Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol (2005) 2.08
A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation. COPD (2012) 2.07
Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis. Am J Respir Cell Mol Biol (2013) 2.06
Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med (2011) 2.06
Variant IRAK-1 haplotype is associated with increased nuclear factor-kappaB activation and worse outcomes in sepsis. Am J Respir Crit Care Med (2006) 2.05
Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med (2007) 2.04
Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med (2003) 2.03
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98
Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.98
Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med (2007) 1.94
The effects of pulmonary rehabilitation in the national emphysema treatment trial. Chest (2005) 1.94
Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist (2010) 1.91
A new powerful non-parametric two-stage approach for testing multiple phenotypes in family-based association studies. Hum Hered (2003) 1.89
Sensitization to Ascaris lumbricoides and severity of childhood asthma in Costa Rica. J Allergy Clin Immunol (2007) 1.88
Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax (2010) 1.82
CT metrics of airway disease and emphysema in severe COPD. Chest (2009) 1.81
Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med (2012) 1.80
Genome-wide study of percent emphysema on computed tomography in the general population. The Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study. Am J Respir Crit Care Med (2014) 1.80
Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest (2008) 1.80
Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.79
Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med (2007) 1.77
Clinical and radiographic predictors of GOLD-unclassified smokers in the COPDGene study. Am J Respir Crit Care Med (2011) 1.76